Michael Milks, MD
Cardiovascular Disease · Gahanna, OHNPI 1740576644
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,645 of the $1,680 with a category attached, or 97.9%. United Therapeutics Corporation accounts for 97.9% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for cardiovascular disease clinicians in OH, where the typical reported total is $1,347.
Across 2 payments — averaging $839.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$2K
- Amgen$35
Across 7 payments — averaging $14,460 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$48K
- Novartis$33K
- Amgen$20K
What the payments were for
- Consulting fees$1,64598%
- Food & beverage$352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 1 | $1,645 |
| Amgen | 1 | $35 |
How this compares
$1,680 in reported general payments places this provider in the 50th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 396 | $316,599 |
| EliquisApixaban | 161 | $206,569 |
| JardianceEmpagliflozin | 60 | $90,055 |
| Praluent PenAlirocumab | 91 | $74,267 |
| EntrestoSacubitril/Valsartan | 30 | $45,641 |
| XareltoRivaroxaban | 36 | $30,085 |
| VascepaIcosapent Ethyl | 20 | $20,518 |
| Ezetimibe | 324 | $10,949 |
| Colesevelam Hcl | 14 | $6,955 |
| Icosapent Ethyl | 23 | $6,807 |
| Ranolazine ErRanolazine | 12 | $5,531 |
| Rosuvastatin Calcium | 344 | $5,300 |
| Metoprolol Succinate | 204 | $3,593 |
| Omega-3 Acid Ethyl Esters | 27 | $2,673 |
| Atorvastatin Calcium | 194 | $1,799 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Gahanna
- Guilherme AttizzaniCleveland$1.3M
- Gregory LamCircleville$428K
- Emil HayekHudson$379K
- Abraham LincoffCleveland$369K
- Oussama WazniCleveland$367K
- Ian NeelandCleveland$329K
- Kamal ShemisaCincinnati$314K
- Mehdi ShishehborElyria$237K
- Abdu HawwaGarfield Hts$234K
- Jayanta MukherjeeColumbus$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.